H.R. 3029 Congress 119 session
To amend the Research and Development, Competition, and Innovation Act to support nucleic acid screening, and for other purposes.
Nucleic Acid Standards for Biosecurity Act This bill explicitly requires the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis. Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), carry genetic information within cells. Nucleic acid synthesis is the process of designing and creating custom nucleic acids; it is used in the development of medications and agricultural products. However, this technology also poses a risk of misuse (e.g., the intentional or unintentional creation of dangerous biological agents). The bill requires NIST to carry out measurement research to support the development and improvement of biosecurity best practices and technical standards related to nucleic acid synthesis. This effort must address specified topics including nucleic acid synthesis screening, operational security, and conformity assessment. (A 2023 executive order titled Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence directed NIST to develop and refine similar specifications and best practices for use by synthetic nucleic acid providers. NIST's work on this topic is ongoing.) In carrying out this effort, NIST must convene stakeholders to develop and periodically update consensus priorities and best practices for synthetic nucleic acid screening mechanisms. Within a specified period, NIST must submit a summary of the stakeholder group’s findings to Congress. NIST must also take steps to advance risk management best practices and technical standards for engineering biology and biomanufacturing, including with respect to risks associated with the use of artificial intelligence.
Status
- Introduced
- Committee
- Floor vote
- Passed
- Enacted
Passed one chamber — last recorded action July 21, 2026
Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
Passage likelihood
64% Higher than most bills at this stage
This is an estimate, not a guarantee. It is computed from the signals listed below and nothing else. It does not account for leadership priorities, floor scheduling, or negotiations that are not in the public record.
What the estimate is based on
- Historical base rate About 4% of introduced federal bills are enacted.
- Current stage Passed one chamber.
- Cosponsors 3 cosponsors.
- Bipartisan cosponsorship Cosponsors come from 2 parties.
State-level impact
State-level impact data is not available for this bill. The source text does not contain a per-state funding formula or scored breakdown, so no figures are shown.
Official actions
- Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
- Motion to reconsider laid on the table Agreed to without objection.
- On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4666)
- Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H4666)
- DEBATE - The House proceeded with forty minutes of debate on H.R. 3029.
- Considered under suspension of the rules. (consideration: CR H4666-4667)
- Mr. Babin moved to suspend the rules and pass the bill, as amended.
- Placed on the Union Calendar, Calendar No. 654.
- Reported by the Committee on Science, Space, and Technology. H. Rept. 119-751.
- Reported by the Committee on Science, Space, and Technology. H. Rept. 119-751.
- Ordered to be Reported by Voice Vote.
- Committee Consideration and Mark-up Session Held
- Referred to the House Committee on Science, Space, and Technology.
- Introduced in House
- Introduced in House